{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:00:00Z","timestamp":1789275600376,"version":"build-2803163510"},"posted":{"date-parts":[[2025,8,23]]},"group-title":"Cancer Biology","reference-count":53,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"id":[{"id":"https:\/\/ror.org\/001ader08","id-type":"ROR","asserted-by":"publisher"}]},{"name":"UCSF Living Therapeutics Initiative"},{"name":"UCSF Stephen and Nancy Grand Multiple Myeloma Translational Initiative"},{"id":[{"id":"https:\/\/ror.org\/03ww1bx13","id-type":"ROR","asserted-by":"publisher"}]},{"name":"NIH Medical Scientist Training Program","award":["T32GM141323"],"award-info":[{"award-number":["T32GM141323"]}]},{"name":"NCI","award":["P30CA082103"],"award-info":[{"award-number":["P30CA082103"]}]},{"name":"Myeloma Solutions Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,8,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Despite the success of BCMA CAR-Ts, many multiple myeloma patients relapse and require additional therapeutic options. Our group previously identified the chemokine receptor CCR10 as a potential alternate target to address this need. Here, we validated CCR10 expression on primary myeloma tumors and sought to develop CAR T-cells against CCR10, utilizing its natural ligand CCL27 as a CAR binding element. However, CARs based on the native CCL27 sequence were ineffective. We thus utilized computational modeling and structure-guided engineering to inform rational mutations along the CCL27-CCR10 interface, exploiting a hydrophobic pocket on CCR10. This effort identified CCL27 mutants with an additional N-terminal aromatic amino acid that dramatically improved the efficacy of CCL27-based CAR-Ts to near that of current anti-BCMA CAR-Ts. We validated key amino acid contacts at the CCL27-CCR10 interface, which contribute to increased CAR binding avidity, predicted to be influenced by increased Van der Waals interactions. Lastly, we found that the CCL27 mutants have no toxicity in the hematopoietic compartment. This work illustrates the potential of engineering natural ligand CAR-Ts beyond their wild-type sequences and underscores the translational potential of engineered CCL27 mutant CAR-Ts.<\/jats:p>","DOI":"10.1101\/2025.08.19.670119","type":"posted-content","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T22:25:12Z","timestamp":1755987912000},"source":"Crossref","is-referenced-by-count":2,"title":["Structure-guided engineering of CCL27 enhances natural ligand CAR T-cells against CCR10 for multiple myeloma"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3456-8144","authenticated-orcid":false,"given":"Nikhil","family":"Chilakapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonell","family":"Pati\u00f1o-Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"de Montagnac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrik S.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Akagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Phojanakong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Salangsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama D.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Shy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Steri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Karlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Kortemme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-6964","authenticated-orcid":false,"given":"Arun P.","family":"Wiita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2025082606550497000_2025.08.19.670119v1.1","doi-asserted-by":"crossref","unstructured":"Firestone, R. S. & Mailankody, S . Current use of CAR T cells to treat multiple myeloma. Hematology 2023, 340\u2013347 (2023).","DOI":"10.1182\/hematology.2023000434"},{"key":"2025082606550497000_2025.08.19.670119v1.2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41587-021-00929-0","article-title":"First CAR-T therapy to target BCMA gets FDA nod","volume":"39","year":"2021","journal-title":"Nat. Biotechnol"},{"key":"2025082606550497000_2025.08.19.670119v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2"},{"key":"2025082606550497000_2025.08.19.670119v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"2025082606550497000_2025.08.19.670119v1.5","doi-asserted-by":"crossref","unstructured":"Fu, B. , Liu, R. , Gao, G. , Lin, Z. & He, A . Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy. Front. Immunol. 15, (2024).","DOI":"10.3389\/fimmu.2024.1433774"},{"key":"2025082606550497000_2025.08.19.670119v1.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017848"},{"key":"2025082606550497000_2025.08.19.670119v1.7","unstructured":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy | Nature Medicine. https:\/\/www.nature.com\/articles\/s41591-021-01564-7."},{"key":"2025082606550497000_2025.08.19.670119v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00631-7"},{"key":"2025082606550497000_2025.08.19.670119v1.9","first-page":"1","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025082606550497000_2025.08.19.670119v1.10","unstructured":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells | Science Translational Medicine. https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.aau7746?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed."},{"key":"2025082606550497000_2025.08.19.670119v1.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"2025082606550497000_2025.08.19.670119v1.12","doi-asserted-by":"crossref","unstructured":"Ferguson, I. D. et al. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nat. Commun. 13, 4121 (2022).","DOI":"10.1038\/s41467-022-31810-6"},{"key":"2025082606550497000_2025.08.19.670119v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01853-0"},{"key":"2025082606550497000_2025.08.19.670119v1.14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.9.6309"},{"key":"2025082606550497000_2025.08.19.670119v1.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.7.3465"},{"key":"2025082606550497000_2025.08.19.670119v1.16","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-012-2927-3"},{"key":"2025082606550497000_2025.08.19.670119v1.17","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2015.105"},{"key":"2025082606550497000_2025.08.19.670119v1.18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1042\/BST20230358","article-title":"Structural perspectives on chemokine receptors","volume":"52","year":"2024","journal-title":"Biochem. Soc. Trans"},{"key":"2025082606550497000_2025.08.19.670119v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2015.15"},{"key":"2025082606550497000_2025.08.19.670119v1.20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.6.2943"},{"key":"2025082606550497000_2025.08.19.670119v1.21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000703"},{"key":"2025082606550497000_2025.08.19.670119v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.04.001"},{"key":"2025082606550497000_2025.08.19.670119v1.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025536"},{"key":"2025082606550497000_2025.08.19.670119v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1039-5"},{"key":"2025082606550497000_2025.08.19.670119v1.25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006699"},{"key":"2025082606550497000_2025.08.19.670119v1.26","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez-Chac\u00f3n, A. et al. Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments. Front. Immunol. 13, (2022).","DOI":"10.3389\/fimmu.2022.932559"},{"key":"2025082606550497000_2025.08.19.670119v1.27","first-page":"165","article-title":"Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30","volume":"71","year":"2021","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"2025082606550497000_2025.08.19.670119v1.28","doi-asserted-by":"crossref","unstructured":"Duan, Y. et al. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell. Mol. Life Sci. CMLS 79, 14 (2021).","DOI":"10.1007\/s00018-021-04089-x"},{"key":"2025082606550497000_2025.08.19.670119v1.29","doi-asserted-by":"crossref","unstructured":"He, C. , et al. CD19 CAR antigen engagement mechanisms and affinity tuning. Sci. Immunol. 8, eadf1426 (2023).","DOI":"10.1126\/sciimmunol.adf1426"},{"key":"2025082606550497000_2025.08.19.670119v1.30","doi-asserted-by":"crossref","unstructured":"Li, D. et al. Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours. Nat. Commun. 14, 5920 (2023).","DOI":"10.1038\/s41467-023-41631-w"},{"key":"2025082606550497000_2025.08.19.670119v1.31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-22-1769","article-title":"Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma","volume":"83","year":"2023","journal-title":"Cancer Res"},{"key":"2025082606550497000_2025.08.19.670119v1.32","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.22.24309250"},{"key":"2025082606550497000_2025.08.19.670119v1.33","unstructured":"Single cell type - CCR10 - The Human Protein Atlas. https:\/\/www.proteinatlas.org\/ENSG00000184451-CCR10\/single+cell#single_cell_type_summary."},{"key":"2025082606550497000_2025.08.19.670119v1.34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-013458"},{"key":"2025082606550497000_2025.08.19.670119v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-024-07487-W"},{"key":"2025082606550497000_2025.08.19.670119v1.36","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1021\/acs.jmedchem.6b01309","article-title":"Structural Analysis of Chemokine Receptor\u2013Ligand Interactions","volume":"60","year":"2017","journal-title":"J. Med. Chem"},{"key":"2025082606550497000_2025.08.19.670119v1.37","doi-asserted-by":"crossref","unstructured":"Tiller, K. E. et al. Facile Affinity Maturation of Antibody Variable Domains Using Natural Diversity Mutagenesis. Front. Immunol. 8, 986 (2017).","DOI":"10.3389\/fimmu.2017.00986"},{"key":"2025082606550497000_2025.08.19.670119v1.38","first-page":"e5021","article-title":"A Flow Cytometry\u2013Based Method for Assessing CAR Cell Binding Kinetics Using Stable CAR Jurkat Cells","volume":"14","year":"2024","journal-title":"Bio-Protoc"},{"key":"2025082606550497000_2025.08.19.670119v1.39","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jpcb.7b11367"},{"key":"2025082606550497000_2025.08.19.670119v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/nm0202-157"},{"key":"2025082606550497000_2025.08.19.670119v1.41","unstructured":"Genotyping Protocol. Synthego https:\/\/www.synthego.com\/resources\/genotyping-protocol."},{"key":"2025082606550497000_2025.08.19.670119v1.42","doi-asserted-by":"crossref","unstructured":"Angelini, A. et al. Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis. Nat. Commun. 9, 1461 (2018).","DOI":"10.1038\/s41467-018-03687-x"},{"key":"2025082606550497000_2025.08.19.670119v1.43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cellimm.2005.08.017","article-title":"Cross-reactivity of anti-human chemokine receptor and anti-TNF family antibodies with common marmoset (Callithrix jacchus) leukocytes","volume":"236","year":"2005","journal-title":"Cell. Immunol"},{"key":"2025082606550497000_2025.08.19.670119v1.44","unstructured":"AI conjures up potential new antibody drugs in a matter of months. https:\/\/www.science.org\/content\/article\/ai-conjures-potential-new-antibody-drugs-matter-months."},{"key":"2025082606550497000_2025.08.19.670119v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0290-5"},{"key":"2025082606550497000_2025.08.19.670119v1.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1805-z"},{"key":"2025082606550497000_2025.08.19.670119v1.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07018-7"},{"key":"2025082606550497000_2025.08.19.670119v1.48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.it.2025.01.001","article-title":"CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells","volume":"46","year":"2025","journal-title":"Trends Immunol"},{"key":"2025082606550497000_2025.08.19.670119v1.49","doi-asserted-by":"crossref","unstructured":"Mollica Poeta, V. , Massara, M. , Capucetti, A. & Bonecchi, R. Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy. Front. Immunol. 10, (2019).","DOI":"10.3389\/fimmu.2019.00379"},{"key":"2025082606550497000_2025.08.19.670119v1.50","doi-asserted-by":"publisher","DOI":"10.1042\/bst20201114"},{"key":"2025082606550497000_2025.08.19.670119v1.51","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl3995"},{"key":"2025082606550497000_2025.08.19.670119v1.52","unstructured":"UCSF ChimeraX: Tools for structure building and analysis - Meng - 2023 - Protein Science - Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pro.4792."},{"key":"2025082606550497000_2025.08.19.670119v1.53","doi-asserted-by":"crossref","first-page":"e0119532","DOI":"10.1371\/journal.pone.0119532","article-title":"Ratiometric Analysis of Fura Red by Flow Cytometry: A Technique for Monitoring Intracellular Calcium Flux in Primary Cell Subsets","volume":"10","year":"2015","journal-title":"PLOS ONE"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.08.19.670119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T09:23:53Z","timestamp":1768469033000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2025.08.19.670119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":53,"URL":"https:\/\/doi.org\/10.1101\/2025.08.19.670119","relation":{},"subject":[],"published":{"date-parts":[[2025,8,23]]},"subtype":"preprint"}}